Teriflunomide
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Teriflunomide
Teriflunomide: Known uses and market status in Australia
Summary
The TxGNN model’s candidates for Teriflunomide are all known uses, so there is currently no new predicted indication. The one candidate that can be traced to a source is relapsing-remitting multiple sclerosis, which is already supported by a licence in another country. This page therefore lists known uses only.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| relapsing-remitting multiple sclerosis | licence in another country; approved indication: multiple sclerosis |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 2898M | Teriflunomide Sandoz | Tablet 14 mg | Valid |
Cytotoxicity
Teriflunomide is an immunomodulator, not an antineoplastic drug, so this section does not apply.
Safety Considerations
- Drug Interactions: The data compiled for this report list 100 interactions, with 20 shown. Most flagged are Major, including:
- Corticosteroids (hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone)
- Antidiabetic agents (acarbose, pioglitazone)
- Bupropion, acetylsalicylic acid, clarithromycin, minocycline
- Chenodeoxycholic acid, oxandrolone, oxymetholone
- Moderate interactions include alosetron, cimetidine, empagliflozin and sitagliptin. Minor interactions include zinc sulfate and zinc acetate.
- Additional guardrails noted in the analysis: monitor for hepatotoxicity, avoid use in pregnancy because of teratogenicity, and use the accelerated elimination procedure when required. Haematological adverse effects are a recognised concern.
Product-specific warnings and contraindications were not available. Please refer to the TGA-approved Product Information (PI) for full safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.